229028-67-5

Basic information

• Product Name: Alanine, 3-cyano-N-[(1,1-dimethylethoxy)carbonyl]- (9CI)
• Synonyms: Alanine, 3-cyano-N-[(1,1-dimethylethoxy)carbonyl]- (9CI)
• CAS NO: 229028-67-5
• Molecular Formula: C9H14N2O4
• Molecular Weight: 214.21846
• Product Categories: N-BOC
• Mol File: 229028-67-5.mol

Chemical Properties

• Boiling Point: 408.6±40.0 °C(Predicted)
• Appearance: /
• Density: 1.204±0.06 g/cm3(Predicted)
• PKA: 3.06±0.10(Predicted)
• CAS DataBase Reference: Alanine, 3-cyano-N-[(1,1-dimethylethoxy)carbonyl]- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Alanine, 3-cyano-N-[(1,1-dimethylethoxy)carbonyl]- (9CI)(229028-67-5)
• EPA Substance Registry System: Alanine, 3-cyano-N-[(1,1-dimethylethoxy)carbonyl]- (9CI)(229028-67-5)

Safety Data

• Hazardous Substances Data: 229028-67-5(Hazardous Substances Data)

Upstream product

• 7536-55-2 N-tert-butyloxycarbonylasparagine 

Relevant articles and documents

INHIBITORS OF THROMBOSIS

This invention relates to peptide aldehyde analogs that inhibit the thrombin or Factor Xa. The compounds are thought useful for preventing or treating conditions in mammal characterized by abnormal thrombosis.

Alpha-KETOAMIDE DERIVATIVES AS INHIBITORS OF THROMBOSIS

a-Ketoamide derivatives, their pharmaceutically acceptable salts, compositions, diagnostic compositions and pharmaceutical compositions, which are useful for preventing or treating in a mammal a pathological condition characterized by thrombosis are described. a-Ketoamide derivatives, their pharmaceutically acceptable salts, compositions and diagnostic compositions, which are useful for in vivo imaging of thrombi in a mammal are also described. Methods of preventing or treating in a mammal a pathological condition characterized by thrombosis and methods of in vivo imaging of thrombi in a mammal are also disclosed.

INHIBITORS OF THROMBOSIS

This invention relates to peptide aldehyde analogs that inhibit the thrombin or Factor Xa. The compounds are thought useful for preventing or treating conditions in mammal characterized by abnormal thrombosis.

TRYPSIN INHIBITORS

Novel compounds having activity against trypsin are disclosed. Specifically, novel peptide aldehyde analogues that have substantial potency and specificity as inhibitors of mammalian pancreatic trypsin are presented. The compounds are useful in the prevention and treatment of the tissue damage or destruction associated with pancreatitis.